{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-011851","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2025-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.670645+00:00","generated_at":"2026-05-26T22:57:01.932264+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Replimune Q3 net loss $66.3M; FDA accepts RP1 BLA with priority review, PDUFA July 22","bullets":["FDA accepted BLA for RP1+nivolumab in advanced melanoma with Priority Review; PDUFA date July 22, 2025.","Net loss $66.3M for fiscal Q3 2025, up from $51.1M in Q3 2024; R&D expense $48.0M.","Cash & investments $536.5M as of Dec 31, 2024, expected to fund operations into Q4 2026.","Public offering raised ~$156M net to support RPx development and potential commercial launch.","First patients enrolled in RP2 registration-directed trial for uveal melanoma and Phase 2 HCC trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-011851","json":"https://secwatch.observer/filing/0001104659-25-011851.json","markdown":"https://secwatch.observer/filing/0001104659-25-011851.md","text":"https://secwatch.observer/filing/0001104659-25-011851.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465925011851/0001104659-25-011851-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465925011851/tm256243d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:57:01.932264+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}